A study of Rivastigmine (Multiday Transdermal Patch) the treatment of Alzheimer's disease.
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 09 Mar 2017 According to a Luye Pharma media release, the Federal Institute for Drugs and Medical Devices in Germany (the German health authority) granted approval to commence clinical trials for Rivastigmine Multiday Transdermal Patch (Rivastigmine MD) for the treatment of Alzheimer's disease.
- 09 Mar 2017 New trial record